28 April 2023
SHARE NOW
Cell Therapy
Scaling Up
Viral/Non-Viral Vectors
Katja Betts, CEO at PROGEN, discusses the core issues affecting biotechs working with AAV and how these could be addressed at both the individual team and industry-wide levels.
Katja begins by introducing the challenges facing biotechs within AAV, and explores the possibility for devising standards for the field. Katja continues to explore challenges that occur when scaling up AAV operations, before sharing her top tips for developing AAV.
Finally, Katja discusses her AAV ‘headline highlights’ from the past year or so, and suggests what we might be able to expect from the next 5 years.
This interview has been produced in partnership with PROGEN and was recorded at Advanced Therapies Week 2023.
More like this
Must-See Sessions at Advanced Therapies Week 2025: Ry Leahy, Head of Content, Phacilitate
Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
10 January 2025
ATW Speaker Patrick M Gailliot Previews Event and Discusses His Role in Autologous Cell and Gene Therapies
We caught up with Patrick M Gailliot, Sr. Director, Patient Operations at Abeona Therapeutics, to talk to him about why his work gives him so much joy, preview his session at Advanced Therapies Week in Dallas, and explain the value he gets from the event.
26 November 2024
Texas Cell and Gene Manufacturing Landscape
Ahead of Advanced Therapies Week 2025 in Dallas, we take a look at the Texas cell and gene manufacturing landscape.
19 November 2024
